Pfizer Inc. [NYSE: PFE] gained 1.22% or 0.59 points to close at $49.04 with a heavy trading volume of 19876315 shares. The company report on May 6, 2022 that Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis.
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information the Agency requested from the companies regarding bone mineral density. The extended Prescription Drug User Fee Act (PDUFA) goal date is August 6, 2022.
“We remain confident in the clinical profile of MYFEMBREE and its potential to become a therapeutic option for the management of endometriosis-associated pain,” said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, Inc. “We will continue to work closely with the FDA to support the ongoing review of the sNDA.”.
It opened the trading session at $48.09, the shares rose to $49.215 and dropped to $48.04, the range by which the price of stock traded the whole day. The daily chart for PFE points out that the company has recorded 11.84% gains over the past six months. However, it is still -29.19% lower than its most recent low trading price.
If we look at the average trading volume of 29.92M shares, PFE reached to a volume of 19876315 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:
Morgan Stanley have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 06, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price from $59 to $70. The new note on the price target was released on January 05, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise from $44 to $65, while Bernstein kept a Mkt Perform rating on PFE stock. On December 20, 2021, analysts increased their price target for PFE shares from 56 to 70.
The Average True Range (ATR) for Pfizer Inc. is set at 1.62, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.96. The Price to Book ratio for the last quarter was 3.57, with the Price to Cash per share for the same quarter was set at 5.57. Price to Free Cash Flow for PFE in the course of the last twelve months was 12.95 with Quick ratio for the last quarter at 1.20.
Trading performance analysis for PFE stock
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.06. With this latest performance, PFE shares dropped by -7.24% in over the last four-week period, additionally plugging by 11.84% over the last 6 months – not to mention a rise of 23.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 43.64, with the RSI for the last a single of trading hit 43.57, and the three-weeks RSI is set at 44.54 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 50.81, while it was recorded at 48.96 for the last single week of trading, and 49.47 for the last 200 days.
Pfizer Inc. [PFE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +25.58 and a Gross Margin at +57.67. Pfizer Inc.’s Net Margin is presently recorded at +27.57.
Return on Equity for this stock inclined to 31.92, with Return on Assets sitting at 13.35.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
Pfizer Inc. [PFE]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -0.80%.
An analysis of insider ownership at Pfizer Inc. [PFE]
There are presently around $185,497 million, or 68.30% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 465,274,925, which is approximately 1.159% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 409,985,644 shares of the stock with an approximate value of $20.11 billion in PFE stocks shares; and STATE STREET CORP, currently with $13.97 billion in PFE stock with ownership of nearly 1.792% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,634 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 192,801,550 shares. Additionally, 1,409 investors decreased positions by around 134,843,749 shares, while 295 investors held positions by with 3,454,911,649 shares. The mentioned changes placed institutional holdings at 3,782,556,948 shares, according to the latest SEC report filing. PFE stock had 314 new institutional investments in for a total of 48,083,416 shares, while 138 institutional investors sold positions of 18,991,773 shares during the same period.